Workshop on integration site analysis during long term follow-up for gene therapies with integrating viral vectors (from Catapult’s regulatory round-up for November 2024)
The FDA’s CBER Office of Therapeutic Products (OTP) hosted a virtual scientific public workshop on 14th November 2024 to discuss the clinical use of integration site analysis (ISA) during long term follow-up following administration of gene...